PHASE 1/2 STUDY OF THOR-707 (SAR444245), A PEGYLATED RECOMBINANT NON-ALPHA IL-2, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB OR CETUXIMAB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS

Gerald Falchook, Hui Gan, Siqing Fu, Meredith McKean, Arun Azad, David Sommerhalder, Judy Wang, Tira Tan, Chen Chee, Minal Barve, Charlotte Lemeque, Nicole Acuff, Helene Pham, Jill Mooney, Rui Wang, Neyssa Marina, Giovanni Abbadessa, Tarek Meniawy

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)A511-A511
Number of pages1
JournalJournal for immunotherapy of cancer
Volume9
DOIs
Publication statusPublished - Nov 2021

Cite this